[go: up one dir, main page]

IN2014DN00123A - - Google Patents

Download PDF

Info

Publication number
IN2014DN00123A
IN2014DN00123A IN123DEN2014A IN2014DN00123A IN 2014DN00123 A IN2014DN00123 A IN 2014DN00123A IN 123DEN2014 A IN123DEN2014 A IN 123DEN2014A IN 2014DN00123 A IN2014DN00123 A IN 2014DN00123A
Authority
IN
India
Prior art keywords
compounds
mek
inflammation
inhibitors
cancer
Prior art date
Application number
Inventor
Ramulu Poddutoori
Can Wang
Xianglin Zhao
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Priority to IN123DEN2014 priority Critical patent/IN2014DN00123A/en
Publication of IN2014DN00123A publication Critical patent/IN2014DN00123A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

The present invention relates to compounds (I) and pharmaceutically acceptable salts thereof. The compounds have been demonstrated as inhibitors of MEK and therefore may be useful in the treatment of hyperproliferative diseases like cancer and inflammation.
IN123DEN2014 2011-06-09 2012-06-06 IN2014DN00123A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN123DEN2014 IN2014DN00123A (en) 2011-06-09 2012-06-06

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN1634DE2011 2011-06-09
CN201210175145 2012-05-31
IN123DEN2014 IN2014DN00123A (en) 2011-06-09 2012-06-06
PCT/IB2012/052860 WO2012168884A1 (en) 2011-06-09 2012-06-06 Heterocyclic sulfonamide derivatives

Publications (1)

Publication Number Publication Date
IN2014DN00123A true IN2014DN00123A (en) 2015-05-22

Family

ID=46384435

Family Applications (1)

Application Number Title Priority Date Filing Date
IN123DEN2014 IN2014DN00123A (en) 2011-06-09 2012-06-06

Country Status (10)

Country Link
EP (1) EP2718276A1 (en)
JP (1) JP2014517004A (en)
KR (1) KR20140034898A (en)
AU (1) AU2012265844A1 (en)
BR (1) BR112013031201A2 (en)
CA (1) CA2838029A1 (en)
EA (1) EA201391820A1 (en)
IN (1) IN2014DN00123A (en)
MX (1) MX2013014398A (en)
WO (1) WO2012168884A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013094546A1 (en) * 2011-12-19 2013-06-27 住友化学株式会社 Method for producing sulfonate
EP3251673A1 (en) 2012-12-13 2017-12-06 IP Gesellschaft für Management mbH Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
CN104886052B (en) * 2015-06-02 2016-08-31 吉林省八达农药有限公司 A kind of application of cyclopropyl-sulfonylamide
JP2020521741A (en) * 2017-05-25 2020-07-27 アラクセス ファーマ エルエルシー Compounds for the treatment of cancer and methods of their use
WO2019183385A1 (en) * 2018-03-22 2019-09-26 University Of Rochester Mapk/erk inhibition for ovarian and other cancers

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (en) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Ring gap magnet system
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
EP0100172B1 (en) 1982-07-23 1987-08-12 Imperial Chemical Industries Plc Amide derivatives
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
US5395855A (en) 1990-05-07 1995-03-07 Ciba-Geigy Corporation Hydrazones
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
TW225528B (en) 1992-04-03 1994-06-21 Ciba Geigy Ag
DE69233803D1 (en) 1992-10-28 2011-03-31 Genentech Inc Use of vascular endothelial growth factor antagonists
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
EP2163546B1 (en) 1995-03-30 2016-06-01 Pfizer Products Inc. Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
TR199800012T1 (en) 1995-07-06 1998-04-21 Novartis Ag Pyrolopyrimidines and applications for preparation.
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
DE69710712T3 (en) 1996-04-12 2010-12-23 Warner-Lambert Co. Llc REVERSIBLE INHIBITORS OF TYROSINE KINASEN
CA2258548C (en) 1996-06-24 2005-07-26 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
NZ334821A (en) 1996-08-30 2000-12-22 Novartis Ag Method for producing epothilones
ATE247724T1 (en) 1996-09-06 2003-09-15 Obducat Ab METHOD FOR ANISOTROPIC ETCHING STRUCTURES IN CONDUCTIVE MATERIALS
DE19638745C2 (en) 1996-09-11 2001-05-10 Schering Ag Monoclonal antibodies against the extracellular domain of the human VEGF receptor protein (KDR)
AU4342997A (en) 1996-09-13 1998-04-02 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the reatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
DK0941227T5 (en) 1996-11-18 2009-10-05 Biotechnolog Forschung Gmbh Epothilone D, its preparation and its use as a cytostatic agent and as a plant protection agent
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
CO4950519A1 (en) 1997-02-13 2000-09-01 Novartis Ag PHTHALAZINES, PHARMACEUTICAL PREPARATIONS THAT UNDERSTAND THEM AND THE PROCESS FOR THEIR PREPARATION
CO4940418A1 (en) 1997-07-18 2000-07-24 Novartis Ag MODIFICATION OF A CRYSTAL OF A DERIVATIVE OF N-PHENYL-2-PIRIMIDINAMINE, PROCESSES FOR ITS MANUFACTURE AND USE
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
CA2322157C (en) 1998-02-25 2012-05-29 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
ES2342240T3 (en) 1998-08-11 2010-07-02 Novartis Ag ISOQUINOLINE DERIVATIVES WITH ACTIVITY INHIBITED BY ANGIOGENIA.
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
UA71587C2 (en) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Anthranilic acid amides and use thereof as medicaments
NZ511722A (en) 1998-11-20 2004-05-28 Kosan Biosciences Inc Recombinant methods and materials for producing epothilone and epothilone derivatives
EP1140173B2 (en) 1998-12-22 2013-04-03 Genentech, Inc. Vascular endothelial cell growth factor antagonists and uses thereof
DE60028740T2 (en) 1999-03-30 2007-05-24 Novartis Ag PHTHALAZINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES
PE20020354A1 (en) 2000-09-01 2002-06-12 Novartis Ag HYDROXAMATE COMPOUNDS AS HISTONE-DESACETILASE (HDA) INHIBITORS
AR035885A1 (en) 2001-05-14 2004-07-21 Novartis Ag DERIVATIVES OF 4-AMINO-5-FENIL-7-CYCLLOBUTILPIRROLO (2,3-D) PYRIMIDINE, A PROCESS FOR ITS PREPARATION, A PHARMACEUTICAL COMPOSITION AND THE USE OF SUCH DERIVATIVES FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
JP2006083137A (en) * 2004-09-17 2006-03-30 Sankyo Co Ltd Immunosuppressive agent
ES2547303T3 (en) * 2007-01-19 2015-10-05 Ardea Biosciences, Inc. MEK inhibitors
CA2924418A1 (en) * 2007-07-30 2009-02-05 Jean-Michel Vernier Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same
WO2009112490A1 (en) * 2008-03-11 2009-09-17 Cellzome Limited Sulfonamides as zap-70 inhibitors
KR20110029161A (en) * 2008-07-01 2011-03-22 제넨테크, 인크. Bicyclic heterocycles as MEB kinase inhibitors
AU2009344690A1 (en) * 2009-04-21 2011-10-27 Novartis Ag Heterocyclic compounds as MEK inhibitors
CN102134218A (en) * 2009-06-15 2011-07-27 凯美隆(北京)药业技术有限公司 6-aryl amino pyridone sulfamide and 6-aryl amino pymetrozine sulfamide methyl ethyl ketone (MEK) inihibitor
BR112012010519A2 (en) * 2009-11-04 2017-12-05 Novartis Ag heterocyclic sulfonamide derivatives
ES2484171T3 (en) * 2009-12-08 2014-08-11 Novartis Ag Heterocyclic sulfonamide derivatives

Also Published As

Publication number Publication date
BR112013031201A2 (en) 2017-01-31
MX2013014398A (en) 2014-03-21
KR20140034898A (en) 2014-03-20
JP2014517004A (en) 2014-07-17
WO2012168884A1 (en) 2012-12-13
EP2718276A1 (en) 2014-04-16
CA2838029A1 (en) 2012-12-13
EA201391820A1 (en) 2014-12-30
AU2012265844A1 (en) 2013-05-02

Similar Documents

Publication Publication Date Title
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
EP4647076A3 (en) Therapeutically active compounds and their methods of use
AU2012214029A8 (en) Rorgammat inhibitors
IN2014KN00769A (en)
MX2011011083A (en) Heterocyclic compounds as mek inhibitors.
IN2015DN01156A (en)
ZA201700572B (en) Therapeutically active compounds and their methods of use
EP2750694B8 (en) Methods and compositions relating to p62 for the treatment and prophylaxis of cancer
TN2012000465A1 (en) Derivatives of 1-amino-2-cyclopropylethylboronic acid
IN2014MN00948A (en)
MX349159B (en) Deuterated derivatives of ivacaftor.
IN2014MN00987A (en)
PH12014501829A1 (en) Bicyclic pyrazinone derivatives
IN2015DN01119A (en)
MX2014003376A (en) Benzoic acid derivatives as eif4e inhibitors.
MX345127B (en) Thiazole derivatives.
EA032271B9 (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
HK1223924A1 (en) Therapeutically active compounds and their methods of use
IN2014DN00123A (en)
TN2012000242A1 (en) Heterocyclic sulfonamide derivatives
IN2014DN03010A (en)
IN2014CN02315A (en)
MX2015007945A (en) Uses and methods for the treatment of liver diseases or conditions.
AU2012307449A8 (en) Sulfonic acid salts of heterocyclylamide-substituted imidazoles
MX348147B (en) Bisarylsulfonamides useful in the treatment of inflammation and cancer.